$CLOV stock has now risen 8% today, according to our price data from Polygon. There has been approximately $17,507,051 of trading volume.
Here is what we see in our data on $CLOV (you can track the company live on Quiver's $CLOV stock page):$CLOV Insider Trading Activity
$CLOV insiders have traded $CLOV stock on the open market 12 times in the past 6 months. Of those trades, 4 have been purchases and 8 have been sales.
Here’s a breakdown of recent trading of $CLOV stock by insiders over the last 6 months:
- VIVEK GARIPALLI has made 2 purchases buying 446,980 shares for an estimated $998,996 and 0 sales.
- CONRAD WAI (CEO, Counterpart Health) has made 0 purchases and 2 sales selling 209,797 shares for an estimated $692,968.
- JAMIE L. REYNOSO (CEO, Medicare Advantage) has made 0 purchases and 6 sales selling 56,000 shares for an estimated $155,511.
- ANNA U LOENGARD has made 2 purchases buying 26,500 shares for an estimated $68,755 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$CLOV Hedge Fund Activity
We have seen 118 institutional investors add shares of $CLOV stock to their portfolio, and 89 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. added 20,029,317 shares (+193.2%) to their portfolio in Q2 2025, for an estimated $55,881,794
- GEODE CAPITAL MANAGEMENT, LLC added 4,812,368 shares (+95.7%) to their portfolio in Q2 2025, for an estimated $13,426,506
- MILLENNIUM MANAGEMENT LLC removed 4,745,791 shares (-81.8%) from their portfolio in Q2 2025, for an estimated $13,240,756
- STATE STREET CORP added 4,580,664 shares (+156.5%) to their portfolio in Q2 2025, for an estimated $12,780,052
- VANGUARD GROUP INC added 3,665,917 shares (+17.8%) to their portfolio in Q2 2025, for an estimated $10,227,908
- BANK OF AMERICA CORP /DE/ added 2,748,783 shares (+217.5%) to their portfolio in Q2 2025, for an estimated $7,669,104
- NORTHERN TRUST CORP added 2,341,788 shares (+226.4%) to their portfolio in Q2 2025, for an estimated $6,533,588
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$CLOV Analyst Ratings
Wall Street analysts have issued reports on $CLOV in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Canaccord Genuity issued a "Buy" rating on 08/07/2025
To track analyst ratings and price targets for $CLOV, check out Quiver Quantitative's $CLOV forecast page.
$CLOV Price Targets
Multiple analysts have issued price targets for $CLOV recently. We have seen 2 analysts offer price targets for $CLOV in the last 6 months, with a median target of $3.55.
Here are some recent targets:
- Richard Close from Canaccord Genuity set a target price of $4.1 on 08/07/2025
- Jonathan Yong from UBS set a target price of $3.0 on 08/06/2025
You can track data on $CLOV on Quiver Quantitative.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
